Inovio Pharmaceuticals (INO) Earnings Date & Reports

Key Takeaways

• Inovio Pharmaceuticals (NASDAQ: INO) is scheduled to report second-quarter 2026 results after the U.S. market close on August 12, 2026, followed by a conference call at 4:30 p.m. Eastern Time.
• The consensus estimate calls for a net loss of $0.24 per share, narrower than the $0.61 loss reported in the prior-year quarter.
• Revenue is expected to remain minimal because the company does not yet have an approved product generating commercial sales.
• Investor focus is likely to center on regulatory progress for lead candidate INO-3107 and the company's cash position rather than on quarterly revenue.
• Management previously projected an operational net cash burn of approximately $18 million for the second quarter of 2026.

Earnings Context and Why It Matters

Inovio is a clinical-stage biotechnology company developing DNA (deoxyribonucleic acid) medicines for human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Because its lead candidate, INO-3107, is not yet approved, this earnings report is less about sales growth and more about two questions: whether the company is making progress toward a potential U.S. Food and Drug Administration (FDA) approval, and whether its cash can fund operations through that decision. With a target FDA decision date of October 30, 2026, the second-quarter update arrives at a pivotal moment for investors assessing clinical, regulatory, and financing risk.

Earnings Expectations

Wall Street analysts expect Inovio to report a net loss of approximately $0.24 per share for the second quarter. That compares with a net loss of $0.61 per share in the second quarter of 2025. Reported revenue is expected to be negligible, reflecting the company's clinical-stage status and the absence of an approved commercial product.

In the first quarter of 2026, Inovio reported total operating expenses of $21.9 million and a net loss of $19.7 million, or $0.28 per share. Research and development (R&D) expenses were $14.1 million, while general and administrative (G&A) expenses were $7.9 million. Management has guided to an operational net cash burn of about $18 million for the second quarter of 2026.

Beyond the income statement, key metrics include cash, cash equivalents, and short-term investments; any update to the company's projected cash runway; and commentary on the regulatory review timeline for INO-3107. Investors will also listen for updates on commercial readiness and the potential need for additional financing.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Inovio and broader biotechnology peers, it can provide a structured way to monitor evolving market conditions and signal-based opportunities.

Market Reaction and Investor Sentiment

Sentiment heading into the second-quarter report remains cautious. Inovio shares have traded under pressure as investors weigh the company's financing needs, share dilution from recent capital raises, and the binary regulatory outcome for INO-3107. Analyst ratings reflect a mixed view, with some firms maintaining constructive long-term outlooks tied to the lead program while others remain neutral on near-term execution and balance-sheet risk. For a pre-revenue biotech, the stock's reaction may be driven less by the earnings per share print itself and more by any new information on the FDA review, cash runway, or commercial launch preparations.

Forward Outlook and Key Factors to Monitor

The most important catalyst remains the FDA review of INO-3107 for recurrent respiratory papillomatosis (RRP), a rare and chronic respiratory disease caused by HPV types 6 and 11. Inovio's Biologics License Application (BLA) was accepted for review in December 2025 under the FDA's accelerated approval pathway, with a Prescription Drug User Fee Act (PDUFA) target action date of October 30, 2026.

Investors should monitor whether the FDA completes the late-cycle review and whether the previously discussed informal meeting on accelerated-approval eligibility provides clarity. Any update on the confirmatory trial design or potential approval timing could be a significant market-moving event.

Cash and financing remain central. As of March 31, 2026, Inovio reported cash, cash equivalents, and short-term investments of $37.7 million, excluding about $16.0 million in net proceeds from an April 2026 public offering. Management has said current balances are expected to fund operations into the first quarter of 2027, beyond the PDUFA date, but that projection excludes future capital-raising activities. Additional equity financings could support the balance sheet while also creating dilution risk.

Finally, watch for updates on commercial readiness and competition in the RRP market, as well as progress on earlier-stage pipeline programs such as INO-5412 in glioblastoma. These factors may shape how investors frame the company's longer-term opportunity following the quarterly update.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.